Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Anamorelin is a ghrelin receptor agonist launched in Japan that brings a new treatment option to cancer cachexia patients by increasing appetite and weight.What drugs does Anamorel···【more】
Article source：Captain MedicineRelease date：2024-08-22Recommended：243
Koselugois a precision small molecule MEK inhibitor designed for specific tumor types, especially in the treatment of neurofibromatosis (NF1).Is Koselugoeffective?The therapeutic e···【more】
Article source：Captain MedicineRelease date：2024-08-22Recommended：315
Koselugo is a carefully developed small molecule MEK blocker (also known as a mitogen activation inhibitor) whose core medical strategy focuses on precisely targeting targeted inte···【more】
Article source：Captain MedicineRelease date：2024-08-22Recommended：307
As the world's first drug specifically for the treatment of cachexia, Anamorelin helps patients restore their appetite and increase weight and muscle mass by stimulating ghreli···【more】
Article source：Captain MedicineRelease date：2024-08-22Recommended：213
Anamorelin is a drug that mimics the function of ghrelin in the human body, which can increase appetite and increase muscle mass, and is used to improve weight and appetite problem···【more】
Article source：Captain MedicineRelease date：2024-08-22Recommended：205
Koselugo is a carefully developed small molecule MEK inhibitor (also known as a Schengen-activated antagonist) with a focus on precisely targeted therapies for specific tumor types···【more】
Article source：Captain MedicineRelease date：2024-08-22Recommended：259
Koselugo is a class of finely designed small molecule MEK blockers (also known as mitogen activation inhibitors), and its core therapeutic strategy is targeted therapy for specific···【more】
Article source：Captain MedicineRelease date：2024-08-22Recommended：258
Koselugo is a precisely targeted small molecule MEK inhibitor with a therapeutic focus on targeted therapies targeting specific tumor types, especially in the treatment of neurofib···【more】
Article source：Captain MedicineRelease date：2024-08-22Recommended：269
Koselugo is a class of precision small molecule MEK inhibitors (also regarded as schizogenic activation antagonists), and its core efficacy focuses on targeted therapy for specific···【more】
Article source：Captain MedicineRelease date：2024-08-22Recommended：235
Koselugo is a small molecule MEK inhibitor (figogen activation inhibitor) that is mainly used for the treatment of certain types of tumors, especially in the treatment of neurofibr···【more】
Article source：Captain MedicineRelease date：2024-08-22Recommended：235
Anamorelin is a drug for cancer cachexia that increases a patient's appetite and weight by mimicking the effects of ghrelin. This drug can significantly improve the nutritional···【more】
Article source：Captain MedicineRelease date：2024-08-21Recommended：279
As a selective ghrelin receptor agonist, anamolin is approved in Japan for improving the health of cancer cachexia patients. By promoting appetite and gaining weight, it has a posi···【more】
Article source：Captain MedicineRelease date：2024-08-21Recommended：217
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：1632025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：4002024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：1552025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：1752025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：1552025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：1892025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：1692025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：1652025-27-11
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
